Seres Therapeutics, Inc. MCRB today announced that management will present at two upcoming investor conferences:
- H.C. Wainwright 22nd Annual Global Investment Conference: Seres will present a corporate overview on Wednesday, September 16 at 11:00 a.m. ET.
- Oppenheimer Fall Healthcare Summit: Seres will present a corporate overview on Wednesday, September 23 at 11:40 a.m. ET.
A live audio webcast of each presentation will be available under the "Investors and Media" section of Seres' website. A replay of the presentations will become available approximately one hour after the event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., MCRB is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is developing SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 for ulcerative colitis and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005065/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.